Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Compugen Ltd.
  6. Company
    CGEN   IL0010852080

COMPUGEN LTD.

(CGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Number of employees : 68 people.
Sales per Business
20192020Delta
Therapeutic Products--2.00100%-
USD in Million
Sales per region
2020
Europe2.00100%
USD in Million
Managers
Name Title Age Since
Anat Cohen-Dayag, Dr. President, Chief Executive Officer & Director 53 2014
Ari Krashin Chief Operating & Financial Officer 47 2016
Henry Adewoye, Dr. Chief Medical Officer 55 2018
Arie Ovadia, Dr. Director 70 -
Elana Holzman Director-IR & Corporate Communications - 2017
Zurit Levine, Dr. Vice President-Technology Innovation 52 -
Tsipi Keren-Lehrer Vice President-Business Development - 2013
Riki Schwartz Vice President-Research & Discovery - 2018
Oliver Froescheis, Dr. Senior VP-Corporate & Business Development - 2020
Eran Ben-Dor General Counsel - -
Members of the board
Name Title Age Since
Paul Jai Sekhri Chairman 62 2017
Arie Ovadia, Dr. Director 70 -
Anat Cohen-Dayag, Dr. President, Chief Executive Officer & Director 53 2014
Gilead Halevy Director 54 2018
Sanford S. Zweifach Non-Executive Director 64 2018
Kinneret Livnat-Savitsky, Dr. Director 52 2018
Jean-Pierre Bizzari, Dr. Director 67 2018
Earn Perry Director - 2019
Barrie Ramsay Zesiger Director 74 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 83,917,929 79,044,024 94.2% 0 0.0% 94.2%
Shareholders
NameEquities%
ARK Investment Management LLC 9,832,678 11.7%
Nikko Asset Management Americas, Inc. 7,027,400 8.37%
RA Capital Management LP 2,957,434 3.52%
Raging Capital Management LLC 2,703,564 3.22%
Consonance Capital Management LP 2,637,421 3.14%
Tavistock Life Sciences Co. (Investment Management) 2,383,673 2.84%
Presidio Management Group, Inc. 1,965,250 2.34%
The Vanguard Group, Inc. 1,845,567 2.20%
Meitav Tachlit Mutual Funds Ltd. 1,298,804 1.55%
KSM Mutual Funds Ltd. 1,287,267 1.53%
Company contact information
Compugen Ltd.
Azrieli Center
26 Harokmim Street
Building D
Holon, Tel Aviv 58858

Phone : +972.3.765.8585
Fax : +972.3.765.8555
Web : http://www.cgen.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Compugen Ltd.
Sector Other Biotechnology & Medical Research